Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gatifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | POLB | P06746 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | CLK2 | P49760 | 1/20 | 0.98 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gatifloxacin SCHEMBL3565683 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL29765369 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL1380257 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL3565686 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL4818151 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL4818160 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL1380256 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL1046589 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (R)-Gatifloxacin SCHEMBL5670068 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL30910969 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288301-A1 | Novel crystalline forms of gatifloxacin | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS. | 2005-12-29 | — | — | US | claimed |
| EP-1492535-B1 | ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN) | REDDYS LAB LTD DR (IN) | 2005-10-26 | — | — | EP | claimed |
| CN-1665504-A | Novel crystalline forms of gatifloxacin | TEVA PHARMA (IL) | 2005-09-07 | — | — | CN | claimed |
| EP-1503762-A2 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-02-09 | — | — | EP | claimed |
| US-20040009989-A1 | Novel crystalline forms of gatifloxacin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-15 | — | — | US | claimed |
| WO-2003094919-A2 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-20 | — | — | WO | claimed |
| US-12351369-B2 | Inner plug constituting nozzle and eye drop container | ZACROS CORPORATION (JP) | 2025-07-08 | — | — | US | disclosed |
| US-12285930-B2 | Ophthalmic solution container | ZACROS CORPORATION (JP) | 2025-04-29 | — | — | US | disclosed |
| US-20230094702-A1 | Inner Plug Constituting Nozzle And Eye Drop Container | FUJIMORI KOGYO CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20230088243-A1 | Inner Plug Constituting Nozzle And Eye Drop Container | ZACROS CORPORATION (JP) | 2023-03-23 | — | — | US | disclosed |
| CN-115066226-A | Inner plug constituting nozzle and eye drop container | 藤森工业株式会社 | 2022-09-16 | — | — | CN | disclosed |
| US-20220055357-A1 | OPHTHALMIC SOLUTION CONTAINER | ZACROS CORPORATION (JP) | 2022-02-24 | — | — | US | disclosed |
| CN-113302133-A | Eye drop container | 藤森工业株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-20050085640-A1 | Novel crystalline forms of gatifloxacin | HETERO DRUGS LIMITED (IN) | 2005-04-21 | — | — | US | disclosed |
| EP-1492535-A1 | ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN) | Dr. Reddy's Laboratories Ltd. (IN) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004087688-A1 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | HETERO DRUGS LIMITED (IN) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003086402-A1 | ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN) | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-10-23 | — | — | WO | disclosed |
| EP-0805156-B1 | 8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE WITH EXCELLENT STABILITY AND PROCESS FOR PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-5880283-A | Gatifloxacin hydrate | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0805156-A1 | 8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE WITH EXCELLENT STABILITY AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085640-A1 | Novel crystalline forms of gatifloxacin | GATD3, PDE6C, UACA | KDM4E 2456/4885ALDH1A1 4600/4885HPGD 2692/4885 |
| US-20050288301-A1 | Novel crystalline forms of gatifloxacin | RECQL, GATD3, CYP2F1 | KDM4E 4328/4885ALDH1A1 3892/4885HPGD 1380/4885 |
| US-20040009989-A1 | Novel crystalline forms of gatifloxacin | RECQL, GATD3, CYP2F1 | KDM4E 4328/4885ALDH1A1 3892/4885HPGD 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.